PFM Health Sciences’s Centessa Pharmaceuticals CNTA Stock Holding History

PFM Health Sciences’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-528,224	Closed	-$21M	–	102
2026 Q1	$21M	Sell	528,224 -63,377	-11%	-$1.62M	1.91%	13
2025 Q4	$14.8M	Sell	591,601 -74,595	-11%	-$1.89M	1.48%	26
2025 Q3	$16.2M	Buy	666,196 +321,224	+93%	+$5.71M	1.24%	26
2025 Q2	$4.53M	Sell	344,972 -225,574	-40%	-$2.86M	0.39%	43
2025 Q1	$8.2M	Buy	570,546 +198,780	+53%	+$3.25M	0.6%	37
2024 Q4	$6.23M	Buy	371,766 +102,608	+38%	+$1.7M	0.39%	51
2024 Q3	$4.3M	Sell	269,158 -366,485	-58%	-$4.49M	0.24%	54
2024 Q2	$5.74M	Buy	635,643 +320,969	+102%	+$3.04M	0.28%	56
2024 Q1	$3.56M	Buy	+314,674	New	+$2.98M	0.17%	74

PFM Health Sciences's CNTA Position: Q2 2026 in Review

PFM Health Sciences sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 528,224 shares — an estimated $21M sold.

PFM Health Sciences first reported a position in CNTA in Q1 2024 and held it in 9 quarters. The position peaked at $21M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

PFM Health Sciences reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
PFM Health Sciences sold 528,224 Centessa Pharmaceuticals shares in Q2 2026, an estimated $21M.
PFM Health Sciences first reported a position in Centessa Pharmaceuticals in Q1 2024 and held it in 9 quarters.
PFM Health Sciences's Centessa Pharmaceuticals position peaked at $21M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.